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ABSTRACT: As part of our ongoing eﬀort to expand the
scope of cross-coupling reactions of alkyl electrophiles, we
have pursued a strategy wherein the nucleophilic coupling
partner includes a pendant oleﬁn; after transmetalation by
such a substrate, if β-migratory insertion proceeds faster
than direct cross-coupling, an additional carbon−carbon
bond and stereocenter can be formed. With the aid of a
nickel/diamine catalyst (both components are commer-
cially available), we have established the viability of this
approach for the catalytic asymmetric synthesis of 2,3-
dihydrobenzofurans and indanes. Furthermore, we have
applied this new method to the construction of the
dihydrobenzofuran core of fasiglifam, as well as to a cross-
coupling with a racemic alkyl electrophile; in the latter
process, the chiral catalyst controls two stereocenters, one
that is newly generated in a β-migratory insertion and one
that begins as a mixture of enantiomers.
In recent years, signiﬁcant progress has been reported on thedevelopment of methods for the transition-metal-catalyzed
cross-coupling of alkyl electrophiles to generate carbon−carbon
bonds, including enantioselective processes.1 To date, most
investigations of asymmetric catalysis have focused on stereo-
convergent reactions of racemic secondary electrophiles,2
although an advance has also been described with a racemic
secondary nucleophile (top of Figure 1).3
As part of our ongoing eﬀort to expand the scope of
enantioselective cross-couplings of alkyl electrophiles, we are
pursuing an approach wherein an organometallic reagent that
bears a pendant oleﬁn is employed as the nucleophilic coupling
partner (bottom of Figure 1).4−6 In the presence of a chiral
catalyst, transmetalation and then β-migratory insertion (left
side of Figure 2), followed by alkyl−alkyl coupling, could lead
to the formation of two carbon−carbon bonds and a new
stereocenter (bottom of Figure 1). This strategy complements
asymmetric coupling processes wherein an intermediate of type
A is generated through oxidative addition of an electrophile
(right side of Figure 2).7
In this report, we establish that a transmetalation−insertion
sequence can indeed be used to generate two, rather than one,
carbon−carbon bonds in a cross-coupling with an alkyl
electrophile and that this process can be achieved with good
enantioselectivity. Speciﬁcally, we describe couplings of
arylboron reagents that bear a pendant oleﬁn with unactivated
alkyl halides, thereby furnishing 2,3-dihydrobenzofurans8,9 and
indanes10,11 in high ee (eq 1).
In order to enhance the likelihood of cyclization (β-
migratory insertion) prior to coupling with the electrophile,
we chose to focus on an organometallic coupling partner that
could form a ﬁve-membered ring upon insertion, since such
cyclizations are often facile. At the outset, it was unclear what
catalyst would enable the desired sequence of bond-forming
processes, much less achieve high enantioselectivity.
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Figure 1. Asymmetric cross-couplings of alkyl electrophiles.
Figure 2. Complementary approaches to generating a precursor (A)
for catalytic enantioselective cyclizations.
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Interestingly, we have determined that a nickel/1,2-diamine-
based catalyst, which we have found to be useful for
enantioconvergent alkyl−alkyl couplings,3,12 is also eﬀective
for the desired cyclization/cross-coupling sequence (Table 1,
entry 1). Thus, in the presence of NiBr2·glyme and ligand 1,
both of which are commercially available, the target 2,3-
dihydrobenzofuran is generated in good ee and yield. Under
these conditions, essentially none of the product of direct cross-
coupling (without cyclization of the nucleophile) or of endo
cyclization is observed (<5%).
In the absence of NiBr2·glyme, ligand 1, or i-BuOH, the
desired cyclization/cross-coupling product did not form in
appreciable yield (Table 1, entries 2−4).13 Furthermore, the
use of a smaller excess of the arylboron reagent led to a
somewhat lower ee and yield (entry 5).14 Other ligands that we
have found to be useful for enantioconvergent couplings of
alkyl electrophiles were not eﬀective for this new asymmetric
cross-coupling with an alkyl halide (entries 6−8).15 If the alkyl
bromide was replaced with the corresponding alkyl chloride,
essentially no 2,3-dihydrobenzofuran was observed (entry 9).16
We next examined the scope of this method for asymmetric
cyclization/cross-coupling with alkyl bromides (Table 2).17 A
range of functionalized electrophiles serve as suitable reaction
partners, furnishing the desired 2,3-dihydrobenzofuran in very
good enantiomeric excess. A silane, an acetal, and an imide are
compatible with the reaction conditions. The method is not
limited to unhindered primary alkyl bromides; a β-branched
primary and a secondary bromide also undergo cyclization/
cross-coupling (entries 6 and 7).
Under similar conditions, indane derivatives can also be
produced in high ee, although modest yield (eq 2).17c An
attempt to generate a quaternary stereocenter furnished a
promising initial result (eq 3).
A number of optically active 2,3-dihydrobenzofurans exhibit
interesting biological activity,8,9 including fasiglifam (Takeda
Pharmaceuticals: TAK-875), which progressed to phase 3
clinical trials for type 2 diabetes until being withdrawn due to
concerns about liver safety.18 We have applied our method to a
catalytic asymmetric synthesis of the dihydrobenzofuran core of
fasiglifam (Scheme 1).
Table 1. Catalytic Enantioselective Cyclization/Cross-
Coupling with an Alkyl Electrophile: Inﬂuence of Reaction
Parametersa
aAll data are the average of two experiments. bThe yield was
determined by GC analysis with the aid of a calibrated internal
standard.
Table 2. Catalytic Enantioselective Cyclization/Cross-
Coupling with Alkyl Electrophilesa
aAll data are the average of two experiments. bYield of puriﬁed
product. c15% NiBr2·glyme and 17% ligand 1 were used.
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In view of the similarity of the optimized conditions for this
new asymmetric cyclization/cross-coupling process to those for
our stereoconvergent cross-coupling of racemic γ-halo-
amides,12d we investigated the possibility that a single chiral
catalyst could accomplish two distinct enantioselective trans-
formations: create a new stereocenter through the cyclization of
an achiral nucleophile, as well as control the absolute
stereochemistry of a second stereocenter through an
enantioconvergent coupling of a racemic electrophile. As
illustrated in eq 4, this objective can indeed be achieved
(minor diastereomer: 86% ee).
In summary, we have expanded the scope of cross-coupling
reactions of alkyl electrophiles by incorporating an oleﬁn in the
nucleophilic partner, which leads to the formation of an
additional carbon−carbon bond and stereocenter, when
compared with a simple cross-coupling. With the aid of a
nickel/diamine catalyst (both components are commercially
available), we have established that this strategy enables the
synthesis of highly enantioenriched 2,3-dihydrobenzofurans
and indanes through couplings with a range of alkyl halides. We
have applied this new method to the generation of the
dihydrobenzofuran core of fasiglifam, as well as to a
transformation wherein the chiral catalyst controls the
stereochemistry of two rather diﬀerent processes: a β-migratory
insertion and an enantioconvergent coupling of a racemic alkyl
halide. Ongoing studies are directed at further enlarging the
scope of cross-coupling reactions of alkyl electrophiles, as well
as elucidating the mechanisms of these transformations.
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